Back to today’s briefing

Story perspectives

Breakthrough Drugs Reverse Liver Damage and Fight Fat

2/6/2025

50 4

Summary

Story summary

Efruxifermin, an innovative drug from Akero Therapeutics, is making waves in the fight against metabolic dysfunction-associated steatohepatitis (MASH) by successfully reversing liver scarring. In a parallel breakthrough, researchers at Michigan Medicine have created DT-109, a glycine-based compound that curbs fat buildup and shields the liver from damage in non-human primates, setting the stage for promising clinical trials ahead.

1 of 1

Story summary

Efruxifermin, an innovative drug from Akero Therapeutics, is making waves in the fight against metabolic dysfunction-associated steatohepatitis (MASH) by successfully reversing liver scarring. In a parallel breakthrough, researchers at Michigan Medicine have created DT-109, a glycine-based compound that curbs fat buildup and shields the liver from damage in non-human primates, setting the stage for promising clinical trials ahead.